SEC Info - Sarissa Capital Management LP, et al. - ‘SC 13D’ on 5/17/19 re: Regulus Therapeutics Inc.

Page 12 of 13 Pages

SCHEDULE 13D

EXHIBIT 4

JOINT FILING AGREEMENT

In accordance with Rule 13d−1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Regulus Therapeutics Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 17th day of May, 2019.

SARISSA CAPITAL MANAGEMENT LP

By:	/s/ *Mark DiPaolo*
	Name: Mark DiPaolo
	Title: Senior Partner, General Counsel

SARISSA CAPITAL OFFSHORE MASTER FUND LP

By: Sarissa Capital Offshore Fund GP LLC, its general partner

By:	/s/ *Mark DiPaolo*
	Name: Mark DiPaolo
	Title: Authorized Person

SARISSA CAPITAL CATAPULT FUND LLC

By: Sarissa Capital Management LP, its managing member

By:	/s/ *Mark DiPaolo*
	Name: Mark DiPaolo
	Title: Senior Partner, General Counsel

SARISSA CAPITAL HAWKEYE FUND LP

By: Sarissa Capital Fund GP LP, its general partner

By:	/s/ *Mark DiPaolo*
	Name: Mark DiPaolo
	Title: Authorized Person

/s/*Alexander J. Denner, Ph.D.*
Alexander J. Denner, Ph.D.

CUSIP No. 75915K200

Page 13 of 13 Pages

SCHEDULE 13D

SCHEDULE A

DIRECTORS AND EXECUTIVE OFFICERS OF THE REPORTING PERSONS

The following sets forth the name, position, and principal occupation of each director and executive officer of each of the Reporting Persons. Each such person is a citizen of the United States of America. Except as otherwise indicated, the business address of each director and officer is c/o Sarissa Capital Management LP, 660 Steamboat Road, Greenwich, CT 06830. To the best of the Reporting Persons’ knowledge, except as set forth in this statement on Schedule 13D, none of the directors or executive officers of the Reporting Persons own any Shares.

Name

Position

Alexander J. Denner, Ph.D.

Chief Investment Officer of Sarissa Capital Management LP

Mark DiPaolo

Senior Partner and General Counsel of Sarissa Capital Management LP

Patrice Bonfiglio

Chief Financial Officer and Chief Compliance Officer of Sarissa Capital Management LP

Sarissa Capital Management LP, et al. – ‘SC 13D’ on 5/17/19 re: Regulus Therapeutics Inc. – ‘EX-4’

On: Friday, 5/17/19, at 4:47pm ET · Accession #: 899140-19-406 · File #: 5-87002

Previous ‘SC 13D’: ‘SC 13D’ on 5/16/19 · Next: ‘SC 13D’ on 5/30/19 · Latest: ‘SC 13D/A’ on 12/5/23

General Statement of Beneficial Ownership — Sch. 13D
Filing Table of Contents

‘EX-4’ — Instrument Defining the Rights of Security Holders